Kalaris Therapeutics (KLRS) Interest & Investment Income (2019 - 2026)
Kalaris Therapeutics (KLRS) posted quarterly Interest & Investment Income of -$55000.0 for Q1 2026, down 1016.67% quarter-over-quarter from $6000.0 in Q3 2025.
Kalaris Therapeutics (KLRS) Interest & Investment Income (2019 - 2026) Analysis & Trends
Kalaris Therapeutics' Interest & Investment Income history runs 8 years deep, the most recent figure standing at -$55000.0 for Q1 2026.
- In Q1 2026, Interest & Investment Income changed N/A year-over-year to -$55000.0; the TTM figure through Mar 2026 stood at -$49000.0 (down 4800.0% YoY), while the FY2025 annual figure was $6000.0, changed N/A from the prior year.
- Interest & Investment Income for Q1 2026 stood at -$55000.0, down from $6000.0 in the prior quarter.
- The five-year high for Interest & Investment Income was $5.5 million in Q4 2023, with the low at -$1.3 million in Q4 2022.
- The 5-year median for Interest & Investment Income is -$28000.0 (2024), against an average of $325750.0.
- The sharpest annual moves came in 2022 and 2023: Interest & Investment Income plunged 3866.67% in 2022, then jumped 523.39% in 2023.
- Kalaris Therapeutics' Interest & Investment Income stood at -$1.3 million in 2022, then surged by 523.39% to $5.5 million in 2023, then sank by 100.02% to -$1000.0 in 2024, then jumped by 700.0% to $6000.0 in 2025, then sank by 1016.67% to -$55000.0 in 2026.
- Business Quant data shows KLRS's Interest & Investment Income at -$55000.0 in Q1 2026, $6000.0 in Q3 2025, and -$1000.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Kalaris Therapeutics | 100.19 Mn | 100.19 Mn | - | -24,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -24,000.00 |
| Mar 31, 2026 | -55,000.00 |
| Sep 30, 2025 | 6,000.00 |
| Jun 30, 2024 | -1,000.00 |
| Mar 31, 2024 | -76,000.00 |
| Dec 31, 2023 | 5.47 Mn |
| Sep 30, 2023 | 25,000.00 |
| Jun 30, 2023 | 76,000.00 |
| Mar 31, 2023 | 167,000.00 |
| Dec 31, 2022 | -1.29 Mn |
| Sep 30, 2022 | -119,000.00 |
| Jun 30, 2022 | -94,000.00 |
| Mar 31, 2022 | -195,000.00 |
| Dec 31, 2021 | 82,000.00 |
| Sep 30, 2021 | -3,000.00 |
| Jun 30, 2021 | -16,000.00 |
| Mar 31, 2021 | 42,000.00 |
| Dec 31, 2020 | 595,000.00 |
| Sep 30, 2020 | 112,000.00 |
| Jun 30, 2020 | -134,000.00 |